LungLifeAI Logo

Description of the Business - Update

We are pleased to report that all resolutions proposed in the Special Meeting passed by both interested and disinterested stockholders, as appropriate, and that the deal officially closed on August 7, 2026. The board subsequently set the record date as August 11, 2026. I would like to personally thank you for voting and for your support throughout the years.

The purpose of this letter is to notify you of our paying agents so that we can make the first payment to shareholders expeditiously. A separate shareholder letter will go out in due course.

We have engaged two paying agents due to the nature of our shareholding: SRS Acquiom will manage payments for those who hold shares in certificated form and for whom we have contact information, and MUFG will manage payments for those who have shares held via a nominee or broker as Depositary Interests in the CREST system, as we often do not have visibility into the beneficial holders of those shares or their contact details.

For many of you who hold shares in certificated form, you will soon receive a solicitation e-mail from SRS Acquiom requesting you register in their portal. Please check your inbox or spam folder and complete the request as soon as possible so that we are able to make the first payment.

For those who have dematerialized shares through a broker or custodian, MUFG will make payments to the CREST depository interest (DI) holders directly, which then will be distributed to the beneficial holders via their financial institution.

As stated in the circular and approved by shareholders, there will be two distributions: one in the short term, and the other to follow release of the remaining Holdback amount. This initial distribution will have a payment rate of $0.08/share.

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down